1. COVID-19 threatens M&A already in process— Physician survey shows widespread concern about access to testing and medical supplies for COVID— Novartis cancels $1B generics sale — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Bydureon - Here is the truth

Discussion in 'Amylin' started by Anonymous, Jan 27, 2012 at 5:26 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    You are right that is a real question...a real stupid question. Victoza had spotty access at launch, but that didn't cause them to have no sales.
     

  2. Anonymous

    Anonymous Guest

    I hope they do because docs will ask the patient if they want a once a week version of this stuff. And the patient will say (in your best Paula Dean impression), bless your heart, but I enjoy the extra injections on my butter arse.
     
  3. o2b1

    o2b1 Guest

    Dear Stupid,

    Double negatives are not proper because they make you look and sound like ... well you know, a Victoza rep.

    I dare you,
    o2b1
     
  4. Anonymous

    Anonymous Guest

    Moving Annual Total. $1bn of which is the definition of a blockbuster drug. Victoza has just passed that figure in record time for a diabetes medication (29 months).

    Bydureon could get there but I can't see it being as fast as Victoza or glargine (34 months)
     
  5. Anonymous

    Anonymous Guest

    $168,943,000US are the most recent annual sales (2010) for Shitoza. It didn't do 1bn US in 2011. Maybe in 1bn Kroner, but who gives a fuck about that shitty currency. It takes 8k to equal a dollar.
     
  6. Anonymous

    Anonymous Guest

    No it didn't, it has US$1bn sales worldwide. There are places outside the 50 states you know.

    NB holding onto the Kroner and staying out of the Euro looks like the smartest thing the Danes have ever done.
     
  7. Anonymous

    Anonymous Guest

    We donT need to bash novo reps. They are much better off than we are. I am hoping to get on with them during their expansion. Better stability. Cool culture. I am friends with my novo competitor, and she loves novo. Face it, we,re all just jealous!
     
  8. Anonymous

    Anonymous Guest

    Nice try Novo troll! Cool Culture? Really? Not according to my Novo competitor. Novo is not a nice place to work. Now a big pharma company run by mostly Pfizer rejects.
     
  9. Anonymous

    Anonymous Guest

    Novo just got back from a two day contacting meeting in Tx for institutional reps. This should give the reader a base line of my knowledge..Some worked this weekened after the meeting...That said, yes you have six months to build a product base for your company and yourselfs. you also have time to see how they will position the product.
    Not to mention you are also US company.....and not sending profits over seas.

    It is far easier to keep a job than start a new. So start believing in yourself, not management or even home office.... It's all on you! Rarely does a rep get a chance to be first to market these days... Work your long hours and seek new partnerships with the type II sales folks and yes ask for office patient trials as tacky as it seems. You get 10 patients in each office responding well over six months your golden.

    Also give them the victoza market where it makes sense..and no need to sell on weight loss with new weight loss drugs coming out. Can you name one?

    As mentioned above, you got Texas from me first. B$
     
  10. Anonymous

    Anonymous Guest

  11. Anonymous

    Anonymous Guest

    I took it Friday and it HURTS. I would rather take my victoza than drill the hole in my arm i did w that pen.
     
  12. Anonymous

    Anonymous Guest

    That's funny. It's not a pen. They are suppose to have a pen out later this year or early next year.
     
  13. Anonymous

    Anonymous Guest

    Ok novo rep. you don't know what you are saying cause it is not dosed in a pen yet. Way to show your colors.
     
  14. Anonymous

    Anonymous Guest

    Big ass needle, Nodules at injection site, Black box warning of 2 types of cancer, Pancreatitis. No managed care, Vial and syringe, Complicated delivery system,
    Want me to continue?
     
  15. Anonymous

    Anonymous Guest

    The needle is not an issue for me. It is larger than the Byetta needle, and I find that coaxing the needle in instead of the direct jab works really good. Have a tissue ready to blot and it is no issue at all. First week my blood sugars were so-so, second week very good! I was a bit concerned that the expiration date on the Bydureon was December 2012!

    I have had no nausea and have lost two pounds since I started the medication. I had been on Byetta since 2006.
     
  16. Anonymous

    Anonymous Guest

    How long does it take to teach patients how to mix and inject Bydureon? Who is doing the teaching?
     
  17. Anonymous

    Anonymous Guest

    My Joslin clinic has an RN teaching. Mine took no time at all since I had watched the bydureonbyyourside UK video showing you how to do it. I asked her if I could do the demo since I would be injecting the shot afterwards and she agreed to let me. I performed it flawlessly, then proceeded to inject for the first time. It goes very quickly once you get the hang of it. Today was my third shot and I don't need the reminders anymore, I just do it!
     
  18. Anonymous

    Anonymous Guest

    There are no scare tactics! 34 steps! One of your reps could not even demo for an office! It took him 3 times to get it right.....what a joke!
     
  19. Anonymous

    Anonymous Guest


    Not true! Novo is the best pharma company around! We are expanding when everyone else is downsizing
     
  20. Anonymous

    Anonymous Guest

    Forget Novo folks. They will take the summer off with travel and rest while they Waite for approval. Get as many new starts as possible this summer while they are on R&R.